Stockwatch: Top of the market
This article was originally published in Scrip
It's something neither a long-only biotech fund manager (who picks stocks because of their growth prospects), nor a biotech analyst would ever say; we are close the top of the market in biotech. This is because, if true, it means that investors who can will take their money away from biotech and rotate from the best performing sectors, to those of comparatively lower value.
You may also be interested in...
The impact of the coronavirus pandemic on investors’ portfolios was immediately apparent at the end of the first quarter of 2020. Equity market sell-offs are reflections of investors’ concern for future financial performance which, if material, may have to be announced early.
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.
The prices of biotechnology and pharmaceutical sector indices continue to be comparatively robust in the face of big falls in global markets as investors expect new drugs and vaccines to be generated by the sector. While it is largely accepted that the life science sector will eventually ride to the rescue, bumper profits are far from guaranteed.